Options
Pharmacological Restoration of Visual Function in a Blind Zebrafish Mutant Following Histone Deacetylase Inhibitor (HDACi) Treatment
Date Issued
2016-07
Date Available
2016-07-25T12:22:28Z
Abstract
Background: Controversially, histone deacetylase (HDAC) inhibitors are in clinical trial for the treatment of inherited retinal degenerations. Previous studies report that patients suffering from Retinitis Pigmentosa (RP) show improved visual field and acuity following treatment with the HDAC inhibitor valproic acid (VPA) (Clemson, Tzekov et al. 2011). However, other studies disagree with these findings (van Schooneveld, van den Born et al. 2011) and (Bhalla, Joshi et al. 2013). Thus, we sought to determine if treatment with HDACi rescued visual function and retinal morphology in a blind zebrafish dying-on-edge (dye) mutant identified from a forward genetics screen.
Type of Material
Journal Article
Publisher
British Pharmacological Society
Journal
pA2 Online
Volume
13
Issue
3
Start Page
222P
Language
English
Status of Item
Not peer reviewed
This item is made available under a Creative Commons License
File(s)
Owning collection
Views
1648
Last Month
1
1
Acquisition Date
Mar 28, 2024
Mar 28, 2024
Downloads
217
Last Month
3
3
Acquisition Date
Mar 28, 2024
Mar 28, 2024